Blood-based biomarker prescreening with different testing combinations and cutoffs: A simulation study examining efficacy and cost-effectiveness in Alzheimer's disease prevention studies.

ABSTRACT:

Introduction

Blood-based biomarkers (BBBMs), including plasma amyloid beta (Aβ) or phosphorylated tau (p-tau), combined with apolipoprotein E (APOE) testing, are anticipated to serve as prescreening tools before amyloid positron emission tomography (PET) for recruiting participants for Alzheimer's disease (AD) prevention studies. The predictive efficacy and cost-effectiveness of prescreening may vary with different testing combinations, sequences, and cutoff levels.

Methods

We conducted a simulation study utilizing data from our ongoing Japanese Trial-Ready Cohort (J-TRC) onsite study (n = 202) recruited online. We included cognitively unimpaired individuals who had undergone amyloid PET, APOE genotyping, and evaluation of BBBMs (i.e., plasma Aβ42/Aβ40 r

SUBMITTER: Sato K 

PROVIDER: S-EPMC11891560 | biostudies-literature | 2025 Jan-Mar

REPOSITORIES: biostudies-literature